Avastin: new treatment for cervical cancer

Avastin (bevacizumab) has been approved for the treatment of persistent, recurrent or metastatic carcinoma of the cervix, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in patients who cannot receive platinum.

Avastin (bevacizumab) is also indicated for the treatment of bowel, ovarian and breast cancers. | SCIENCE PHOTO LIBRARY
Avastin (bevacizumab) is also indicated for the treatment of bowel, ovarian and breast cancers. | SCIENCE PHOTO LIBRARY

Approval of bevacizumab for use in advanced cervical cancer was based on the results of a phase III study in 452 patients with persistent, recurrent or late-stage disease. 

In this study, addition of bevacizumab to combination chemotherapy was associated with a significant increase in median overall survival of 3.7 months (17.0 months vs 13.3 months; hazard ratio for death 0.71, 98% CI 0.54–0.95, p=0.004).

Overall, the safety profile was consistent with that seen in previous studies of bevacizumab across different tumour types. An increase in gastrointestinal-vaginal fistulae was observed in patients who received bevacizumab plus chemotherapy compared with those who received chemotherapy alone.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases